Surgical Treatment of Papillary and Follicular Thyroid Carcinoma

International Surgery

Volumn 81, Issue 1, 1996, Pages 61-66

  Lin, Jen Der ^a   Jeng, Long Bin ^a   Chao, Tzu Chieh ^a   Weng, Hsiao Fen ^a   Huang, Hong So ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Kaplan Meier method; Multivariate analysis; Prognostic factors; Thyroid neoplasms; Thyroidectomy

Indexed keywords

THYROGLOBULIN;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHINESE; FEMALE; FROZEN SECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; TAIWAN; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAIWAN; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS;

EID: 0029979007     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-518.
2. Rudgemer IJ, Hay ID, Bergstralh EJ et al. Distant metastasis in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67:501-508.
3. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic finding, therapy, and outcome. Mayo Clin Proc 1986;61:978-996.
4. Hannequin P, Liehn JC, Delisle MJ. Multifactorial analysis of survival in thyroid cancer. Cancer 1986;58:1749-1755.
5. Spiessl B, Beahrs OH, Hermanek P et al. TNM Atlas: Illustrated guide to the TNM/pTMN- classification of malignant tumor. 3rd edition. Berlin, Heidelberg, New York, London, Paris, Tokyo: Springer, 1989:23-25.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:475-481.
7. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trial requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
8. Cox DR. Regression models and life tables. J R Stat Soc 1972;34: 197-219.
9. Samaan NA, Maheshwari YK, Nader S et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 1983;56:1131-1138.
10. Hrafnkelsson J, Jonasson JG, Sigurdsson G, Sigvaldason H, Tulinius H. Thyroid cancer in Iceland 1955-1984. Acta Endocrinol 1988;118:566-572.
11. Simpson WJ, McKinney SE. Canadian survey of thyroid cancer. Can Med Assoc 1985;132:925-931.
12. Chen KP, Lee TY, Hsu PY et al. Study on the effect of salt iodization on endemic goiter, Taiwan. I. Mass survey on goiter of school children. J Formosan Med Assoc 1976;75:471-482.
13. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-953.
14. Simpson WJ, Mckinney SL, Carruthers JS et al. Papillary and follicular thyroid cancer-prognostic factors in 1578 patients. Am J Med 1987;83:479-488.
15. Ruegemer JJ, Hay ID, Bergstralh EJ et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67:501-508.
16. Krausz Y, Uziely B, Karger H et al. Recurrence-associated mortality in patients with differentiated thyroid carcinoma. J Surg Oncol 1993;52:164-168.
17. DeGroot LJ, Kaplan EL, Mccormick M, Straus FH. Nature history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
18. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985;55:805-828.
19. Tubiana M, Schlumberger M, Rougier P et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794-804.
20. Woolner LB. Thyroid carcinoma: pathologic classification with data on prognosis. Semin Nucl Med 1971;1:481-502.
21. Schindler AM, van Melle G, Evequoz B, Scazziga B. Prognostic factors in papillary carcinoma of the thyroid. Cancer 1991;68:324-330.
22. Mueller-Gaertner HW, Brzac HT, Rehpenning W. Prognostic indices for tumor relapse and tumor mortality in follicular thyroid carcinoma. Cancer 1991;67:1903-1911.
23. Samaan NA, Schultz PN, Hickey RC et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-720.
24. Ashcraft MW, van Herle AJ. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 1981;71:806-814.
25. van Herle AJ, Rosenblit PD, van Herle TL et al. Immunoreactive thyroglobulin in sera and saliva of patients with various thyroid disorders: role of autoantidodies. J Endocrinol Invest 1989;12: 171-176.
26. Harvey RD, Matheson NA, Grabowski PS, Rodger AB. Measurement of serum thyroglobulin is of value in detecting tumor recurrence following treatment of differentiated thyroid carcinoma by lobectomy. Br J Surg 1990;77:324-326.
27. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105.
28. Ozaki O, Ito K, Kobayashi K et al. Thyroid carcinoma in Graves' disease. World J Surg 1990;14:437-444.
29. Hales IB, Mcelduff A, Crummer P et al. Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer. J Clin Endocrinol Metab 1992;75:886-889.